Industry Updates
This broad category includes articles concerning health insurance costs, carrier and health plan news, changing benefits technology, and surveys by the Kaiser Family Foundation and others on employee benefits.
House Republicans this week plan to approve expanding health savings accounts—a key tenet of the GOP healthcare platform since they were created under President George W. Bush—and significantly change Obamacare's tax credit structure to let subsidies flow to catastrophic plans.
Nevada’s health insurance rates will increase only slightly in 2019, the state’s Division of Insurance announced Tuesday.
Nevada’s health insurance exchange was injected with yet another dose of uncertainty over the weekend after the Trump administration announced it was stopping payments to insurance companies required under the Affordable Care Act to even out the burden of providing coverage to the sickest patients.
Nevada’s health insurance marketplace, the Silver State Health Insurance Exchange, is one step closer to transitioning onto a state-based operation.
Support staffers in the Clark County School District are lamenting an increase in health insurance costs, saying that higher out-of-pocket costs will leave them financially strapped.
The Trump administration has been pushing for the return of short-term health plans and association health plans, two types of coverage that are exempt from Affordable Care Act requirements and could offer an affordable alternative to consumers who feel priced out of the Obamacare marketplace. But some California advocates say these plans offer shoddy coverage and pose a threat to the stability of the healthcare system.
House Ways and Means Committee Chairman Kevin Brady (R-Texas) said Monday that he is in talks with the Trump administration about ways to restart key ObamaCare payments that the administration abruptly suspended this month.
In a little more than 24 hours, through public shaming and a phone call with Pfizer CEO Ian Read, President Donald Trump convinced the U.S. drug giant to reverse dozens of July price increases—at least temporarily. The extraordinary move signals that pharma players are willing to cede to the president, even as Pfizer and Read have previously resisted limits on their pricing power.
A handful of the world’s biggest drugmakers are canceling or reducing planned price increases in the U.S., following a new California drug pricing transparency law and continued political pressure over pharmaceutical costs.
Despite receiving billions of dollars in taxpayer money, Medicaid insurers are lax in ferreting out fraud and neglect to tell states about unscrupulous medical providers, according to a federal report released Thursday.